Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-2.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.30 0.00 (-0.66%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum C VGM
Cara Therapeutics (CARA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.20 | $8.00 | $1.00 | 932.26% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Cara Therapeutics comes to $3.20. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 932.26% from the last closing price of $0.31.
Analyst Price Targets (5 )
Broker Rating
Cara Therapeutics currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, one is Strong Buy, representing 16.67% of all recommendations. A month ago, Strong Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/13/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Hold |
6/13/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Hold |
6/13/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Hold |
6/13/2024 | Not Identified | Not Identified | Hold | Hold |
5/14/2024 | Piper Sandler | David Amsellem | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 6 |
Average Target Price | $3.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.25 |
CARA FAQs
Cara Therapeutics, Inc. (CARA) currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Cara Therapeutics, Inc. (CARA) is $3.20. The current on short-term price targets is based on 2 reports.
The forecasts for Cara Therapeutics, Inc. (CARA) range from a low of $1 to a high of $8. The average price target represents a increase of $966.67 from the last closing price of $.30.
The current UPSIDE for Cara Therapeutics, Inc. (CARA) is 966.67%
Based on short-term price targets offered by five analysts, the average price target for Cara Therapeutics comes to $3.20. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 932.26% from the last closing price of $0.31.